Quality of life in cutaneous lupus erythematosus

Klein, Rachel S.; Moghadam-Kia, Siamak; Taylor, Lynne; Coley, Christopher M.; Okawa, Joyce; LoMonico, Jonathan; Chren, Mary‐Margaret; Werth, Victoria P.

doi:10.1016/j.jaad.2010.02.008

Cited by 152 publications

(216 citation statements)

References 40 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…QoL was assessed using the Skindex-29 (symptoms, emotions, and functioning, with higher scores indicating worse QoL) and disease severity with the Cutaneous Lupus Erythematosus Disease Area and Severity Index. In this study, CLE had a negative impact on QoL, especially in women with more severe CLE [44]. Similar findings have been reported for body image and HRQoL in SLE by Jolly et al [45].…”

Section: Validated Sle-specific Measuressupporting

confidence: 90%

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

Toloza¹,

Jolly

Alarcón

2010

Curr Rheumatol Rep

View full text Add to dashboard Cite

Although the survival rate for systemic lupus erythematosus (SLE) has improved dramatically during the past 50 years, the quality of life of patients afflicted with this disease remains poor. Currently existent measures of disease activity and damage in SLE do not capture the patient's perspective and health-related quality of life (HRQoL). Most studies in SLE pertaining to HRQoL are from developed Western societies, with only a few from others. These studies have been conducted predominantly in women and using the Medical Outcomes Survey Short Form 36, a generic HRQoL instrument that has been shown not to be sensitive to change in lupus. Existent lupus-specific HRQoL measures have not yet been used in SLE clinical trials. New HRQoL research tools are currently undergoing validation in different countries, languages, and cultural settings, which may help dissect the underlying role of socioeconomic status and specific disease-related features that impact SLE-related quality of life.

show abstract

Section: Validated Sle-specific Measuressupporting

confidence: 90%

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

Toloza¹,

Jolly

Alarcón

2010

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…This result suggests that the QOL of females tended to be worse than males, and is in agreement with previous reports, although the male group in this study was very small. 2,15 Subtypes of LE To assess the relationship between the subtypes of LE and the QOL, we chose SLE and CLE, but excluded MCTD and overlap syndrome because of the complexity of their conditions. The scores from the Skindex-29 decreased significantly after treatment in the three subscales in both SLE and CLE patients (p < 0.005) ( Figure 3).…”

Section: Gendermentioning

confidence: 99%

“…However, the QOL of LE patients with skin manifestations has been reported to be impaired, similar to or worse than several other serious medical disorders in Europe and the USA. [1][2][3] In addition, in systemic lupus erythematosus (SLE), the disease activity and damage, along with poor mental and physical health, have been reported to predict both a reduced QOL and an increased economic burden. 4 Recently, physicians have become more concerned with the issues of QOL in patients with LE, and have started to quantify the QOL and treat them accordingly.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan

Ishiguro

Hashizume

Ikeda

et al. 2013

Lupus

View full text Add to dashboard Cite

The quality of life (QOL) of lupus erythematosus (LE) patients with skin manifestations is impaired, but little is known about Japanese patients. We assessed whether the skin symptoms in LE are associated with the QOL using the Japanese versions of the Skindex-29 and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). In all, 54 LE patients with cutaneous lesions completed the Japanese version of the Skindex-29, and physicians assessed the severity of their eruptions using the CLASI before and after treatment. The QOL of the LE patients was better after the therapeutic intervention using the Skindex-29 questionnaire. We tested several factors for an independent association with the QOL. A significant risk factor for a poor QOL was a female gender in "Functioning" before treatment. In addition, a poor QOL tended to be correlated with a female gender in "Emotions" and older current age in "Symptoms" before treatment, and with a longer duration of SLE in "Functioning" after treatment. In the CLASI analysis, skin manifestation activity in the acute phase correlated with a poor emotional and functional QOL rather than a symptomatic QOL. To the best of our knowledge, this is the first report evaluating the QOL of Japanese LE patients, despite the small cohort.

show abstract

“…The prevalence of CLE is comparable to or higher than that of systemic lupus erythematosus (SLE) [4,5]. Although CLE typically has a less severe course and better prognosis than SLE, it is associated none the less with substantial quality-of-life impairment and work disability because lesions frequently emerge on visible cutaneous areas, such as the face, neck, hands and arms [4,6]. Standard pharmacological treatment of CLE includes topical or systemic corticosteroids and anti-malarial agents, but these options may be of limited effectiveness and may result in burdensome local and systemic side effects [7].…”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus

Masek-Hammerman

Peeva

Ahmad

et al. 2015

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary This study's objective was to assess the effects of PD‐0360324, a fully human immunoglobulin G2 monoclonal antibody against macrophage colony‐stimulating factor in cutaneous lupus erythematosus (CLE). Patients with active subacute CLE or discoid lupus erythematosus were randomized to receive 100 or 150 mg PD‐0360324 or placebo via intravenous infusion every 2 weeks for 3 months. Blood and urine samples were obtained pre‐ and post‐treatment to analyse pharmacokinetics and pharmacodynamic changes in CD14+ CD16+ monocytes, urinary N‐terminal telopeptide (uNTX), alanine/aspartate aminotransferases (ALT/AST) and creatine kinase (CK); tissue biopsy samples were taken to evaluate macrophage populations and T cells using immunohistochemistry. Clinical efficacy assessments included the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). Among 28 randomized/analysed patients, peak/trough plasma concentrations increased in a greater‐than‐dose‐proportional manner with dose increases from 100 to 150 mg. Statistically significant differences were observed between active treatment and placebo groups in changes from baseline in CD14+ CD16+ cells, uNTX, ALT, AST and CK levels at most time‐points. The numbers, density and activation states of tissue macrophages and T cells did not change from baseline to treatment end. No between‐group differences were seen in CLASI. Patients receiving PD‐0360324 reported significantly more adverse events than those receiving placebo, but no serious adverse events. In patients with CLE, 100 and 150 mg PD‐0360324 every 2 weeks for 3 months suppressed a subset of circulating monocytes and altered activity of some tissue macrophages without affecting cell populations in CLE skin lesions or improving clinical end‐points.

show abstract

Quality of life in cutaneous lupus erythematosus

Abstract: Background-Little is known about quality of life in patients with cutaneous lupus erythematosus.

Cited by 152 publications

References 40 publications

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan

Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus

Contact Info

Product

Resources

About